Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Holds Pre-NDA Meeting to Discuss Rivoceranib Plus Camrelizumab for HCC

October 12th 2022

Representatives from Elevar Therapeutics and the FDA held a positive pre–new drug application meeting to discuss the combination of rivoceranib and camrelizumab as a potential therapeutic option for patients with hepatocellular carcinoma.

Understanding the Role of Adjuvant Therapy in Biliary Tract Cancers

October 12th 2022

Experts provide brief perspective on the use of adjuvant treatment approaches for patients with biliary tract cancers.

What is the Role of Transplant in Early-Stage Biliary Tract Cancers?

October 12th 2022

Before closing out their review of early-stage biliary tract cancer treatment options, panelists consider the role of transplant in the setting.

Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management

October 8th 2022

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

Advanced HCC: Updates in First-line Systemic Therapy

October 7th 2022

Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.

Role of Systemic Therapy in Early- or Intermediate-Stage HCC

October 7th 2022

Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.

Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd

October 6th 2022

Panelists share their perspective on the role of the broader, multidisciplinary healthcare team in managing toxicity associated with trastuzumab deruxtecan therapy.

T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea

October 6th 2022

Comprehensive insight on the optimal management of diarrhea associated with ADC therapy, with regard to patient education and monitoring during treatment.

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Derazantinib Demonstrates Promising Efficacy in Intrahepatic Cholangiocarcinoma

October 5th 2022

Patients with locally advanced or metastatic intrahepatic cholangiocarcinoma who received the FGFR inhibitor derazantinib derived a meaningful clinical benefit with a manageable safety profile.

Treatment Options for Early-Stage Biliary Tract Cancers

October 5th 2022

Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.

Guidelines for Molecular Testing in Biliary Tract Cancers

October 5th 2022

Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.

FDA Approves Futibatinib for FGFR2+ Cholangiocarcinoma

September 30th 2022

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

Early- and Intermediate-Stage HCC Treatment Landscape

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.

Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

September 29th 2022

Shifting focus to the second patient profile of HER2+ gastric cancer, key opinion leaders highlight the risk and management of diarrhea in this setting.

Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

September 29th 2022

Panelists briefly review ongoing clinical trials with trastuzumab deruxtecan in the setting of HER2+ gastric cancers.

Biliary Tract Cancers: Staging and Clinicopathologic Features

September 28th 2022

Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.

Challenges in Diagnosing Biliary Tract Cancers

September 28th 2022

Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.

Intraperitoneal Chemotherapy Technique Aims to Dramatically Improve Outcomes in Gastric Carcinomatosis

September 22nd 2022

A novel approach to chemotherapy administration in advanced gastric cancer that has progressed to gastric carcinomatosis is poised to alter the treatment landscape and improve outcomes for this patient population.